In several independent studies, CTGF has been proposed as a biomarker for human diabetic nephropathy and other forms of CKD [8, 10–12] and also for cardiac dysfunction in patients exhibiting myocardial fibrosis and chronic heart failure [13]. Here, CCN2 is linked to diabetic kidney disease.